Home > Boards > US Listed > Medical - Drugs > BIOFRONTERA AG (BFRA)

Biofrontera AG is an international biopharmaceutical company specializing

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 678
Posts 45,510
Boards Moderated 12
Alias Born 12/12/04
160x600 placeholder
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 4/12/2021 5:31:42 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/12/2021 5:17:13 PM
Biofrontera reports Q4 results Seeking Alpha - 4/12/2021 2:05:15 PM
Biofrontera reports results for the 2020 financial year GlobeNewswire Inc. - 4/12/2021 1:57:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 4/8/2021 2:19:40 PM
Biofrontera provides preliminary revenue for 1Q21 Seeking Alpha - 4/8/2021 1:49:44 PM
Biofrontera announces preliminary revenue for Q1 2021 GlobeNewswire Inc. - 4/8/2021 10:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/31/2021 1:54:09 PM
Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results GlobeNewswire Inc. - 3/31/2021 10:12:43 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/31/2021 6:18:52 AM
Biofrontera submits application for FDA approval of new BF-RhodoLEDĀ® XL lamp GlobeNewswire Inc. - 3/31/2021 3:40:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/30/2021 7:22:17 AM
Humanigen, Universe Pharmaceuticals leads healthcare gainers; Millendo Therapeutics, Orphazyme among major losers Seeking Alpha - 3/29/2021 11:00:25 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/16/2021 6:22:23 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/4/2021 6:07:29 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/3/2021 2:53:12 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/3/2021 2:49:56 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/1/2021 1:10:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/26/2021 5:03:36 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/26/2021 10:29:20 AM
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million GlobeNewswire Inc. - 2/26/2021 9:20:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/25/2021 4:28:11 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 2/25/2021 4:06:58 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/25/2021 3:35:03 PM
crudeoil24 Member Level  Tuesday, 02/20/18 09:13:11 AM
Re: crudeoil24 post# 1
Post # of 25 
Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences